Benzinga | Aug 4, 2020 04:37PM EDT

Akcea Therapeutics Q2 EPS $(0.49) Misses $(0.35) Estimate, Sales $22.38M Miss $30.93M Estimate

Akcea Therapeutics (NASDAQ:AKCA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.35) by 40 percent. This is a 22.5 percent decrease over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $22.38 million which missed the analyst consensus estimate of $30.93 million by 27.65 percent. This is a 15.95 percent decrease over sales of $26.62 million the same period last year.